Senators Reintroduce Bill to Study FDI Effects on Pharmaceutical Industry
Two senators reintroduced a bill this month that would require the U.S. to conduct a study on the effects of foreign direct investment on the U.S. pharmaceuticals industry. The U.S. Pharmaceutical Supply Chain Review Act, reintroduced by Sens. Elizabeth Warren,…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
D-Mass., and Marco Rubio, R-Fla., would require the Treasury Department to provide a report to Congress on how foreign direct investment “affects the nation's ability to produce drugs, as well as their key components.” It would also require a report about how foreign investment in “U.S. genome sequencing technologies affects domestic capacity to sequence or store DNA” and the number of transactions that the Committee on Foreign Investment in the U.S. has reviewed in the last year involving the “sequencing or storage of DNA.”